Citi downgrades Novozymes stock to Sell, expects mid-term goals to fall short - Investing.com
| NVZMY Stock | USD 58.24 0.78 1.32% |
Slightly above 62% of Novozymes' investor base is looking to short. The analysis of overall sentiment of trading Novozymes AS pink sheet suggests that many investors are alarmed at this time. Novozymes' investing sentiment can be driven by a variety of factors including economic data, Novozymes' earnings reports, geopolitical events, and overall market trends.
Novozymes |
Citi downgrades Novozymes stock to Sell, expects mid-term goals to fall short Investing.com
Read at news.google.com
 |
Novozymes Fundamental Analysis
We analyze Novozymes' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novozymes using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novozymes based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Book
Price To Book Comparative Analysis
Novozymes is currently under evaluation in price to book category among its peers. Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Novozymes AS Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Novozymes pink sheet to make a market-neutral strategy. Peer analysis of Novozymes could also be used in its relative valuation, which is a method of valuing Novozymes by comparing valuation metrics with similar companies.
Peers
Novozymes Related Equities
| PPG | PPG Industries | 0.52 | ||||
| GVDNY | Givaudan | 0.41 | ||||
| AIQUY | Air Liquide | 0.39 | ||||
| GVDBF | Givaudan | 0.20 | ||||
| SHW | Sherwin Williams | 0.82 | ||||
| IFF | International Flavors | 0.95 | ||||
| APD | Air Products | 0.96 | ||||
| SXYAY | Sika AG | 1.32 | ||||
| SKFOF | Sika AG | 1.87 | ||||
| SYIEY | Symrise Ag | 2.23 | ||||
| ALB | Albemarle Corp | 5.92 |
Additional Tools for Novozymes Pink Sheet Analysis
When running Novozymes' price analysis, check to measure Novozymes' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novozymes is operating at the current time. Most of Novozymes' value examination focuses on studying past and present price action to predict the probability of Novozymes' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novozymes' price. Additionally, you may evaluate how the addition of Novozymes to your portfolios can decrease your overall portfolio volatility.